The lung as a route for systemic delivery of therapeutic proteins and peptides
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wearley LL: Recent progress in protein and peptide delivery by non-invasive routes. Crit Rev Ther Drug Carrier Syst. 1991, 8: 1331-1394.
Wilson CG, Washington N: Physiological Pharmaceutics. England: John Wiley;. 1989
Banga AK: Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems. Lancaster: Technomic;. 1995
Chrystyn H: Is total particle dose more important than particle distribution. Respir Med. 1997, 91(suppl): 17-19.
Gupta S, Moussy F, Dalby RN, Meikka SI, Bruley DF: Pulmonary delivery of human protein C and factor IX. In: Textbook of Advances in Experimental Medicine and Biology or Oxygen Transport to Tissue, vol 411. Edited by Nemoto EM, LaManna J. New York: Plenum Press;. 1997, 429-435.
Engel T, Heinig JH, Malling HJ, Scharling B, Nikander K, Madsen F: Clinical comparison of inhaled busesonide delivered either via pressurized metered dose inhaler or Turbuhaler®. Allergy. 1989, 44: 220-225.
Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H: Flow-dependent effect of formoterol dry powder inhaled from the Aerolizer®. Eur Respir J. 1997, 10: 2105-2109.
Niven RW: Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995, 12: 151-231.
Sayani AP, Chien YW: Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst. 1996, 13: 85-184.
Zhou XH: Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J Contr Rel. 1994, 29: 239-252.
Liu FY, Kildsig DO, Mitra AK: Pulmonary biotransformation of insulin in rat and rabbit. Life Sci. 1992, 51: 1683-1689.
Shen Z, Zhang Q, Wei S, Nagai T: Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations. Int J Pharm. 1999, 192: 115-121.
Fukuda F, Tsuji T, Fujita T, Yamamoto A, Muranishi S: Susceptibility of insulin to proteolysis in rat lung homogenates and its protection from proteolysis by various protease inhibitors. Biol Pharm Bull. 1995, 18: 891-894.
Wigley FM, Londono JH, Wood SH, Shipp JC, Waldman RH: Insulin across respiratory mucosa by aerosol delivery. Diabetes. 1971, 20: 552-556.
Colthorpe P, Farr SJ, Taylor G, Smith IJ, Wyatt D: The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm Res. 1992, 9: 764-768.
Okumura k, Iwaka S, Tsuguchika Y, Toshimitsu S, Komada F: Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int J Pharm. 1992, 88: 63-73.
Sakr FM: A new approach for insulin delivery via the pulmonary route: design and pharmacokinetics in non-diabetics rabbits. Int J Pharm. 1992, 86: 1-7.
Jendle JH, Karlberg BE, Arborelius M: An exploration of intrapulmonary insulin administration in anaesthetized and mechanically ventilated pigs. Scand J Clin Lab Invest. 1996, 56: 251-258.
Jendle JH, Karlberg BE: Intrapulmonary administration of insulin to healthy volunteers. J Intern Med. 1996, 240: 93-98.
Laube BL, Georgopoulos A, Adams GK: Preliminary study of the efficiency of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA. 1993, 269: 2106-2109.
Laube BL, Benedict GW, Dobs AS: The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes. Chest. 1998, 114: 1734-1739.
Laube BL, Benedict GW, Dobs AS: Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. J Aerosol Med. 1998, 11: 153-173.
Pfützner A, Heise T, Steiner S, Heinemann L, Rave K: Inhaled technosphere: insulin shows a low variability in metabolic action in type 2 diabetic patients [abstract]. Diabetes. 2000, 49 (suppl): A121-
Rave KM, Heise T, Pfützner A, Steiner S, Heinemann L: Results of a dose-response study with a new insulin inhaler formulation [abstract]. Diabetes. 2000, 49(suppl): A75-
Elliot RB, Edgar BW, Pitcher CC, Quested C, McMaster J: Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J. 1987, 23: 293-297.
Gelfand AG, Schwartz SL, Horton M, Law CG, Pun EF: Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus (NIDDM) [abstract]. Diabetes. 1998, 47(suppl): A99-
Skyler JS, Gelfand RA, Kourides IA: Treatment of type 1 diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial [abstract]. Diabetes. 1998, 47(suppl): A61-
Cefalu WT, Gelfand RA, Kourides I: Treatment of type 2 diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial [abstract]. Diabetes. 1998, 47(suppl): A61-
Cappelleri JC, Gerber RA, Bell-farrow AD, English JS, Agramonte RF, Kourides IA: Improved patient satisfaction with inhaled insulin in subjects with type 2 diabetes mellitus: results from a multicenter randomized controlled trial [abstract]. Diabetes. 2000, 49(suppl): A100-
Gerber RA, Cappelleri JC, Bell-farrow AD, English JS, Agramonte RF, Gelfand RA: Improved patient satisfaction with inhaled insulin in subjects with type 1 diabetes mellitus after one year: results from a multicenter extension trial [abstract]. Diabetes. 2000, 49(suppl): A108-
Cefalu WT, Balagtas CC, Landschulz WH, Gelfand RA: Sustained efficacy and pulmonary safety of inhaled insulin during two years of outpatient therapy [abstract]. Diabetes. 2000, 49 (suppl): A101-
Farr S, McElduff A, Ward E, Okumu F, Mather L, Gonda I, Rubsamen R: A comparison of the pharmacokinetics and pharmacodynamics of inhaled insulin administered as different strength solutions to healthy volunteers [abstract]. Diabetes. 1998, 47(suppl): A61-
Farr S, McElduff A, Ward E, Okikawa J, Lloyd P, Schuster J, Mather L, Gonda I: The mode of inhalation influences the pharmacokinetics and pharmacodynamics of pulmonary delivered insulin in healthy fasted volunteers [abstract]. Pharm Res. 1997, 14(suppl): S136-
Kipnes M, Otulana B, Clauson P, Fischer J, Farr S, Hatorp V, Schwartz S: A comparison of the pharmacodynamic effects of inhaled insulin versus subcutaneous insulin in type 1 diabetic patients [abstract]. Diabetes. 1999, 48(suppl): A95-
Brunner GA, Balent B, Sendlhofer G, Ellmerer M, Schaupp L, Jendle JH, Kristensen A, Okikawa J, Pieber TR: Pharmacokinetics and pharmcodynamics of inhaled versus subcutaneous insulin in subjects with type 1 diabetes: a glucose clamp study [abstract]. Diabetes. 2000, 49(suppl): A76-
Weiss SR, Berger S, Cheng S, Kourides I, Landschulz WH, Gelfand R: Adjunctive therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: a multicenter phase II trial [abstract]. Diabetes. 1999, 48(suppl): A12-
Patton JS, Trinchero P, Platz RM: Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormone. J Contr Rel. 1994, 28: 79-85.
Komada F, Iwakawa S, Yamamoto N, Sakakibara H, Okumura K: Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J Pharm Sci. 1994, 83: 863-867.
Folkesson HG, Hedin L, Westrom BR, Pierzynowski SG, Karlsson BW: Lung to blood passage of human growth hormone after intratracheal instillation: stimulation of growth in hypophysectomized rats. J Endocrinol. 1992, 134: 197-203.
Colthorpe P, Farr SJ, Smith IJ, Wyatt D, Taylor G: The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharm Res. 1995, 12: 356-359.
Shao Z, Li Y, Mitra AK: Cyclodextrins as mucosal absorption promoters of insulin III: pulmonary route of delivery. Eur J Pharm Biopharm. 1994, 40: 283-288.
Shen Z, Cheny Y, Zhang Q: Lanthanides enhance pulmonary absorption of insulin. Biol Trace Element Res. 2000, 75: 215-225.
Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heis T: Intra-individual variability of metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care. 2000, 23: 1343-1347.
Kobayashi S, Kondo S, Juni K: Study of pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers. Pharm Res. 1994, 11: 1239-1243.
Morita T, Yamamoto A, Takakura Y, Hashida M, Sekaki H: Improvement of pulmonary absorption of (ASU1,7)-Eel calci-tonin by various protease inhibitors in rats. Pharm Res. 1994, 11: 909-913.
Yamamoto A, Okumura S, Fukuda Y, Fukui M, Takahashi K, Muran-ishi S: Improvement of the pulmonary absorption of (ASU1,7)-Eel calcitonin by various absorption enhancers and their pulmonary toxicity in rats. J Pharm Sci. 1997, 86: 1144-1147.
Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R: Large porous particles for pulmonary drug delivery. Science. 1997, 276: 1868-1871.
Kawashima Y, Yamamoto H, Takeuchi H, Fujoka S, Hino T: Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanosphere to prolong hypoglycemic effect. J Contr Rel. 1999, 62: 279-287.
Liu F, Shao Z, Kildsig DO, Mitra AK: Pulmonary delivery of free and liposomal insulin. Pharm Res. 1993, 10: 228-232.
Li Y, Mitra AK: Effect of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm Res. 1996, 13: 76-79.
Smith PL, Yeulet SE, Citerone DR, Drake F, Cook K, Wall DA, Marcello J: SK&F 110679: comparison of absorption following oral or respiratory administration. J Contr Rel. 1994, 28: 67-77.
Ajei A, Garren J: Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy voluteers. Pharm Res. 1990, 7: 565-569.
Adjei A, Johnson E, Doyle R, Sims K: Formulations of a non-apeptide: in vitro and in vivo studies [abstract]. J Pharm Sci. 1987, 76(suppl): PS47-
Adjei A, Hui J, Finley R, Lin T, Lancaster J, Fort F: Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and clinical issues. Int J Pharm. 1994, 107: 57-66.
Bennett DB, Tyson E, Nuremberg CA, Mah S, De Groot JS, Teitelbaum Z: Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in briefly anesthetized dog. Pharm Res. 1994, 11: 1048-1055.
Schreier H, McNicol KJ, Bennette DB, Teitelbaum Z, Derendorf H: Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthethized awake sheep. Pharm Res. 1994, 11: 1056-1059.
Lizio R, Klenner T, Borchard G, Romeis P, Sarlikiotis AW, Reissmann T, Lehr C: Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rat. Eur J Pharm Sci. 2000, 9: 253-258.
Folkesson HG, Westrom BR, Karlsson BW: Permeability of the respiratory tract to different sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol Scand. 1990, 139: 347-354.
Folkesson HG, Westrom BR, Pierzynowski SG, Svendsen J, Karlsson BW: Lung to blood passage of albumin and a nonapeptide after intratracheal instillation in the young developing pig. Acta Physiol Scand. 1993, 147: 173-178.
Bot AI, Tarara TE, Smith DJ, Bot SR, Woods CM, Weers JG: Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res. 2000, 17: 275-283.
Hänninen A, Harisson LC: γδ T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev. 2000, 173: 109-119.
Harrison LC, Dempsey-Collier , Kramer DR, Takahashi K: Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J Exp Med. 1996, 184: 2167-2174.
Altrock BW, Fagin KD, Hockman HR, Fish EN, Goldstein L, Chang D, Duker K, Stebbing N: Antiviral and antitumor effects of human interferon analog, IFN-α Con1, assessed in hamsters. J Interferon Res. 1986, 6: 405-415.
Niven RW, Whitcomb KL, Woodwards M, Liu J, Jornacion C: Systemic absorption and activity of recombinant consensus interferons after intratracheal intillation and aerosol administration. Pharm Res. 1995, 12: 1889-1895.
Niven RW, Lott FD, Cribbs JM: Pulmonary absorption of recombinant methionyl human granulocyte colony stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster. Pharm Res. 1993, 10: 1604-1610.
Niven RW, Lott FD, Ip AY, Cribbs JM: Pulmonary delivery of powders and solutions containing granulocyte colony-stimulating factor (r-huG-CSF) to the rabbit. Pharm Res. 1994, 11: 1101-1109.
Taljanski W, Pierzynowki SG, Lundin PD, Westrom BR, Eirefelt S, Podlesny J, Dahlback M, Siwinska-Golebiowska H, Karlsson BW: Pulmonary delivery of intratracheally instilled and aerosolized cyclosporin A to young and adult rats. Drug Metab Dis. 1997, 25: 917-920.
Niven RW, Whitcomb KL, Shaner LD, Ralph LD, Habberfield AD, Wilson JV: Pulmonary absorption of polyethylene glycolated recombinant human granulocyte colony stimulating factor (PEGr-huG-CSF). J Contr Rel. 1994, 32: 177-189.
Myers MA, Thomas DA, Straub L, Soucy DW, Niven RW, Kaltenback M, Hood CI: Pulmonary effect of chronic exposure to liposome aerosols in mice. Exp Lung Res. 1993, 19: 1-19.